AMARIN CORPORATION PLC (NASDAQ: AMRN)

AMARIN CORPORATION PLC

NASDAQ: AMRN (Amarin Corporation plc)

Last update: 6 hours ago

10.76

0.43 (4.16%)

Add to watchlist

Previous Close	10.33
Open	10.12
Volume	75,634
Avg. Volume (3M)	90,094
Market Cap	222,834,224

Price / Sales	0.930
Price / Book	0.440

52 Weeks Range	7.00 (-34%) — 20.60 (91%)
Earnings Date	7 May 2025

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bearish	Bullish
	Drug Manufacturers - General (Global)	Bearish	Bullish
Stock	Amarin Corporation plc	Bullish	Bullish

AIStockmoo Score

-0.6

Analyst Consensus	-1.5
Insider Activity	-3.0
Price Volatility	-2.0
Technical Moving Averages	1.5
Technical Oscillators	2.0
Average	-0.60

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
AMRN	223 M	-	-	0.440
MIRA	15 M	-	-	7.95
SCLXW	-	-	-	-
AZN	230 B	2.26%	30.43	6.19
SNY	127 B	8.05%	20.32	1.52
AMGN	152 B	3.23%	37.39	25.88

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Sector	Healthcare
Industry	Drug Manufacturers - General
% Held by Insiders	1.76%
% Held by Institutions	20.91%

Ownership

Name	Date	Shares Held
Sarissa Capital Management Lp	31 Dec 2024	1,242,531
Kynam Capital Management, Lp	31 Dec 2024	620,731
Waterfront Wealth Inc.	31 Mar 2025	125,731
Longitude (Cayman) Ltd.	31 Dec 2024	81,000
Eversept Partners, Lp	31 Dec 2024	75,830
Quinn Opportunity Partners Llc	31 Dec 2024	55,327
Hayek Kallen Investment Management	31 Dec 2024	51,216

52 Weeks Range	7.00 (-34%) — 20.60 (91%)
Median	7.00 (-34.94%)
Total	1 Sell

Firm	Date	Target Price	Call	Price @ Call
Goldman Sachs	17 Apr 2025	7.00 (-34.94%)	Sell	9.11

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
BONFIGLIO PATRICE EADON	-	9.11	-437	-3,981
COHEN PAUL	-	9.11	-437	-3,981
DIPAOLO MARK	-	9.11	-437	-3,981
HORN KEITH	-	9.11	-437	-3,981
O'CONNOR OLIVER	-	9.11	-437	-3,981
ODYSSEAS KOSTAS D	-	9.11	-437	-3,981
STERLING LOUIS III	-	9.11	-437	-3,981
SULLIVAN DIANE E.	-	9.11	-437	-3,981
Aggregate Net Quantity				-3,496
Aggregate Net Value ($)				-31,849
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				9.11

Name	Holder	Date	Type	Quantity	Price	Value ($)
DIPAOLO MARK	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
DIPAOLO MARK	Director	18 Apr 2025	Option execute	838	-	-
O'CONNOR OLIVER	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
O'CONNOR OLIVER	Director	18 Apr 2025	Option execute	838	-	-
STERLING LOUIS III	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
STERLING LOUIS III	Director	18 Apr 2025	Option execute	838	-	-
ODYSSEAS KOSTAS D	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
ODYSSEAS KOSTAS D	Director	18 Apr 2025	Option execute	838	-	-
BONFIGLIO PATRICE EADON	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
BONFIGLIO PATRICE EADON	Director	18 Apr 2025	Option execute	838	-	-
HORN KEITH	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
HORN KEITH	Director	18 Apr 2025	Option execute	838	-	-
SULLIVAN DIANE E.	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
SULLIVAN DIANE E.	Director	18 Apr 2025	Option execute	838	-	-
COHEN PAUL	Director	18 Apr 2025	Disposed (-)	437	9.11	3,981
COHEN PAUL	Director	18 Apr 2025	Option execute	838	-	-
Show more

Date	Type	Details
29 Apr 2025	Announcement	Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
28 Apr 2025	Announcement	Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
09 Apr 2025	Announcement	Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
07 Apr 2025	Announcement	Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
31 Mar 2025	Announcement	Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
28 Mar 2025	Announcement	National Triglyceride Alliance Launches to Advance Clinician Education on High Triglycerides and the Importance of Proactive Triglyceride Management
19 Mar 2025	Announcement	New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College o...
19 Mar 2025	Announcement	Concerned Shareholder Group Urges Amarin’s Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance
12 Mar 2025	Announcement	Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
12 Mar 2025	Announcement	Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
27 Feb 2025	Announcement	Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
25 Feb 2025	Announcement	Amarin Receives National Reimbursement for VAZKEPA® in Austria
19 Feb 2025	Announcement	Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	-35.95%
Operating Margin (TTM)	-25.76%
Diluted EPS (TTM)	-4.00
Quarterly Revenue Growth (YOY)	-16.60%

Total Debt/Equity (MRQ)	1.99%
Current Ratio (MRQ)	3.31
Operating Cash Flow (TTM)	-31.02 M
Levered Free Cash Flow (TTM)	8.00 M

Return on Assets (TTM)	-4.56%
Return on Equity (TTM)	-15.83%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)